Psychotic Disorders Clinical Trial
Official title:
Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness
Up to 77% of young people with severe mental illnesses smoke, a rate that is up to five times
higher than the rate of daily smoking in other young adults. Contrary to popular belief,
smoking tobacco does not provide any benefit for mental illness symptom control. People with
severe mental illnesses (SMI: schizophrenia and severe mood disorders) are dying, on average,
25 years earlier than those without SMI. Much of this early mortality is due to higher rates
of heart and lung diseases, cancers, strokes, and diabetes.
Cessation of smoking in these transition-age young adults can prevent cancer and increase
life expectancy to that of non-smokers. Combination treatments are effective in this group
and therefore key to improving outcomes, but few SMI smokers use them despite their interest
in quitting. Motivational interventions for cessation increase interest in quitting, but
public mental health clinicians do not deliver them, in part due to economic reasons. Thus
cost effective methods to deliver motivational interventions to engage young smokers with SMI
into treatment are needed.
To address this gap, we have developed an electronic decision support system (EDSS) for
smoking cessation that is specifically tailored for smokers with SMI, who tend to have
cognitive deficits and limited computer experience. Similar to EDSSs developed for other
health problems, this EDSS provides information and motivational exercises within an
easy-to-use, web-based computer program that can be used with minimal or no staff assistance.
Initial piloting of the EDSS in middle-aged SMI smokers showed excellent usability and
promising efficacy. Pilot-testing among young patients suggested that the EDSS increased
motivation to quit smoking and provided direction to adapt the format and content of the EDSS
for young SMI smokers.
The purpose of this proposal is to further develop the motivational decision support system
and to test its ability to motivate young smokers with SMI to quit smoking with cessation
treatment.
The research will take place over 2 years at the Long Island Zucker Hillside Hospital system.
In Year 1, we will adapt our electronic decision support system, a web-based motivational
tool, for young smokers with severe mental illness. We will first identify beliefs of young
smokers with severe mental illness that impede use of smoking cessation treatments. Then, the
decision support system will be revised to change these beliefs, field-tested for usability,
and improved as needed. In Year 2, we will conduct a randomized control trial of the newly
revised version of the system among 60 young smokers with severe psychotic disorders.
In the controlled trial, participants will be assessed at baseline for mental health symptoms
and smoking behavior and history, and then randomized to use the system or a computerized
public health pamphlet (control condition) within two weeks. Participants will be assessed
again at 14-week follow-up for clinician-confirmed initiation of smoking cessation treatment
(main outcome), beliefs, and smoking characteristics. Analyses will assess whether use of the
decision support system results in greater initiation of cessation treatment (main outcome),
and changes in beliefs about treatment, than use of the control intervention.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00128479 -
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
|
Phase 3 |